本帖最后由 老马 于 2012-1-13 21:20 编辑
4 i1 M. T: U2 v: i% ?: F( Z8 T) W# }; b3 h' i5 z
爱必妥和阿瓦斯丁的比较* L6 r' ]; U( h) g8 a9 s
2 x/ w# \" h" N; K }. J3 Hhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/) H0 a+ e( ~( y% u
' d% k$ `9 \2 b9 O
6 Y) B2 T: i5 B! V$ ihttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
. V3 ?$ [8 s, C7 `$ ^% F+ E==================================================* o4 A" y+ m; _; L
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)+ J1 @3 Z, C3 e4 b
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.2 _& r( O- e, X
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
, T# z0 s, t8 r ~
|